Ipatasertib

Generic Name: Ipatasertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₂ClN_₅O_₂

CAS Number: 1001264-89-6

Unique Ingredient Identifier: 524Y3IB4HQ

Background: Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Refractory Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Refractory Multiple Myeloma
Refractory Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-05-06

Last Posted Date: 2024-11-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06400251

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Phase 3

Recruiting

Conditions: Cancer

Interventions: Drug: Tiragolumab
Drug: Ipatasertib
Drug: Atezolizumab

First Posted Date: 2023-05-17

Last Posted Date: 2025-01-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05862285

Locations: 🇧🇪
GHdC Site Notre Dame, Charleroi, Belgium
🇫🇷
Institut de Cancérologie de Bourgogne, Dijon, France
🇫🇷
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, France

and more 21 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2

Recruiting

Conditions: Metastatic HER2-Negative Breast Carcinoma
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Malignant Female Reproductive System Neoplasm
Recurrent Ovarian Carcinoma
Unresectable HER2-Negative Breast Carcinoma
Unresectable Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Drug: Alpelisib
Drug: Binimetinib
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Ipatasertib
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Nilotinib Hydrochloride Monohydrate
Biological: Panitumumab
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Drug: Sotorasib
Drug: Olaparib
Drug: Fluorouracil
Drug: Neratinib Maleate
Procedure: Mutation Carrier Screening
Drug: Leucovorin
Drug: Fulvestrant
Drug: Selumetinib Sulfate
Procedure: Positron Emission Tomography
Drug: Palbociclib
Procedure: Multigated Acquisition Scan
Drug: Oxaliplatin

First Posted Date: 2022-10-03

Last Posted Date: 2025-01-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2900

Registration Number: NCT05564377

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States

and more 422 locations

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

Phase 2

Recruiting

Conditions: Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel

First Posted Date: 2022-09-26

Last Posted Date: 2025-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT05554380

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States

and more 195 locations

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Phase 1

Recruiting

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Metastatic Endometrial Endometrioid Adenocarcinoma
Recurrent Endometrial Endometrioid Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Drug: Megestrol Acetate

First Posted Date: 2022-09-14

Last Posted Date: 2025-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT05538897

Locations: 🇺🇸
Parkview Regional Medical Center, Fort Wayne, Indiana, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 116 locations

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Phase 1

Active, not recruiting

Conditions: Ovarian High Grade Serous Adenocarcinoma
Unresectable Fallopian Tube High Grade Serous Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Stage III Primary Peritoneal Cancer AJCC v8
Stage IV Ovarian Cancer AJCC v8
Unresectable Fallopian Tube Endometrioid Adenocarcinoma
Unresectable Ovarian Endometrioid Adenocarcinoma
Unresectable Ovarian High Grade Serous Adenocarcinoma

Interventions: Procedure: Biopsy
Drug: Carboplatin
Drug: Ipatasertib
Drug: Paclitaxel

First Posted Date: 2022-03-14

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT05276973

Locations: 🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 6 locations

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Hypopharyngeal Squamous Cell Carcinoma
Metastatic Laryngeal Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Biological: Pembrolizumab

First Posted Date: 2021-12-29

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT05172258

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States

and more 17 locations

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1

Recruiting

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Head and Neck Carcinoma of Unknown Primary
Locally Advanced Head and Neck Squamous Cell Carcinoma
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Locally Advanced Laryngeal Squamous Cell Carcinoma
Locally Advanced Nasal Cavity Squamous Cell Carcinoma
Locally Advanced Oral Cavity Squamous Cell Carcinoma
Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Locally Advanced Paranasal Sinus Squamous Cell Carcinoma
Locally Advanced Sinonasal Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Biopsy
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2021-12-29

Last Posted Date: 2024-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT05172245

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States

and more 13 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1

Recruiting

Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Interventions: Drug: Giredestrant
Drug: Ribociclib
Drug: PH FDC SC
Drug: Abemaciclib
Drug: Ipatasertib
Drug: Inavolisib
Drug: Everolimus
Drug: Samuraciclib
Drug: Atezolizumab
Drug: Palbociclib

First Posted Date: 2021-03-17

Last Posted Date: 2025-01-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 510

Registration Number: NCT04802759

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇮🇱
Rabin MC, Petach Tikva, Israel
🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

and more 25 locations

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Phase 2

Completed

Conditions: Advanced Unresectable or Metastatic Solid Malignancy

Interventions: Drug: Entrectinib
Drug: Inavolisib
Drug: Alectinib
Drug: Ipatasertib
Drug: Atezolizumab
Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Drug: Pralsetinib
Drug: Investigator's Choice of Chemotherapy
Drug: Trastuzumab Emtansine
Drug: Tucatinib
Drug: Paclitaxel
Drug: Tiragolumab

First Posted Date: 2020-11-17

Last Posted Date: 2025-01-08

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 252

Registration Number: NCT04632992

Locations: 🇺🇸
Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States

and more 35 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy